PulmCrit (EMCrit)

Background:  JAK-inhibitors (jakinibs) in the greater context Much of the harm from infections is mediated by hyperactive inflammatory reactions.  To date, most research has focused on two classes of medications to treat this: Corticosteroids have the advantage of being cheap, widely available, and often effective.  The disadvantage is that corticosteroids modulate innumerable molecular pathways, thereby […]

Oximetry is fundamental to critical care.  Consequently, even small biases in pulse oximetry measurements could have real clinical impact (especially when leveraged across innumerable measurements among thousands of patients).    Racial bias in pulse oximetry was the subject of two studies in 2005 and 2007.  The topic was then largely ignored over the past 13 years.  […]

Some studies have reported a gradual upwards trend in the PEEP being used for intubated patients without ARDS (e.g., from 5 cm to 7 cm). Is this good or bad? That is the question which the RELAX trial embarked upon answering. It’s a complex question which probably doesn’t have a binary answer… but never mind – let’s get to the study.

Massive Transfusion Protocols have attracted substantial attention over the past several years, so most folks will be familiar with the general concepts.  This chapter reviews a variety of details which may be essential to the success of an MTP – yet can easily get lost in the chaos. The IBCC chapter is located 👉 here. […]

With the publication of the SOLIDARITY trial, there is increasing consensus that remdesivir doesn’t affect mortality.  However, there continues to be debate about whether remdesivir affects hospital length of stay.  Let’s dig into the data here to try to reconcile differences between ACTT-1 and SOLIDARITY.  Did ACTT-1 actually show that remdesivir reduces the hospital length […]